Reata Pharmaceuticals, Inc. (RETA) Reports Q3 Loss, Lags Revenue EstimatesZacks Investment Research • 11/08/22
Reata Pharmaceuticals, Inc. Announces Third Quarter 2022 Financial Results and Provides an Update on Clinical Development ProgramsBusiness Wire • 11/08/22
Reata Pharmaceuticals, Inc. to Report Third Quarter 2022 Financial Results and to Provide an Update on Clinical Development Programs on November 8, 2022Business Wire • 10/31/22
Reata Pharmaceuticals Announces Presentations at the International Congress for Ataxia Research 2022Business Wire • 10/20/22
Reata Pharmaceuticals, Inc. (RETA) Stock Jumps 20.6%: Will It Continue to Soar?Zacks Investment Research • 10/17/22
Reata Pharmaceuticals Announces that the FDA Does Not Plan to Hold an Advisory Committee Meeting to Discuss the NDA for Omaveloxolone for Friedreich's AtaxiaBusiness Wire • 10/13/22
Reata Pharmaceuticals, Inc. (RETA) Up 4.7% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 09/07/22
Reata Pharmaceuticals Announces Participation in the Citi 17th Annual BioPharma ConferenceBusiness Wire • 09/06/22
Reata Pharmaceuticals Announces Three Month Extension of the Review Period for New Drug Application for Omaveloxolone for the Treatment of Friedreich's AtaxiaBusiness Wire • 08/09/22
Reata Pharmaceuticals, Inc.'s (RETA) CEO Warren Huff on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/08/22
Reata Pharmaceuticals, Inc. (RETA) Reports Q2 Loss, Lags Revenue EstimatesZacks Investment Research • 08/08/22
Reata Pharmaceuticals, Inc. Announces Second Quarter 2022 Financial Results and Provides an Update on Clinical Development ProgramsBusiness Wire • 08/08/22
Reata Pharmaceuticals, Inc. to Report Second Quarter 2022 Financial Results and to Provide an Update on Clinical Development Programs on August 8, 2022Business Wire • 08/01/22
Why Is Reata Pharmaceuticals, Inc. (RETA) Up 53.1% Since Last Earnings Report?Zacks Investment Research • 06/09/22
Reata Pharmaceuticals Announces FDA Filing Acceptance and Priority Review Designation for the NDA for Omaveloxolone for the Treatment of Patients with Friedreich's AtaxiaBusiness Wire • 05/26/22
Reata Pharmaceuticals' (RETA) CEO Warren Huff on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/10/22